These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 16381629

  • 1. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 2. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Dec; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J, Reeves T, Wallace J.
    Oncologist; 2004 Dec; 9(4):451-8. PubMed ID: 15266098
    [Abstract] [Full Text] [Related]

  • 4. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [Abstract] [Full Text] [Related]

  • 5. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 6. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA, Vogel CL, Gralow JR, Williams D, Procrit Study Group.
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.
    Thames WA, Smith SL, Scheifele AC, Yao B, Giffin SA, Alley JL.
    Pharmacotherapy; 2004 Mar; 24(3):313-23. PubMed ID: 15040644
    [Abstract] [Full Text] [Related]

  • 8. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006 Mar; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

  • 9. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV.
    Am J Health Syst Pharm; 2005 Jan 01; 62(1):54-62. PubMed ID: 15658073
    [Abstract] [Full Text] [Related]

  • 10. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct 01; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 11. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
    Glaspy JA, Tchekmedyian NS.
    Oncology (Williston Park); 2002 Oct 01; 16(10 Suppl 11):23-9. PubMed ID: 12435170
    [Abstract] [Full Text] [Related]

  • 12. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Oct 01; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 13. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.
    J Manag Care Pharm; 2008 Oct 01; 14(9):858-69. PubMed ID: 19006442
    [Abstract] [Full Text] [Related]

  • 14. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group.
    J Natl Cancer Inst; 2002 Aug 21; 94(16):1211-20. PubMed ID: 12189224
    [Abstract] [Full Text] [Related]

  • 15. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
    Abdelrazik N, Fouda M.
    Hematology; 2007 Dec 21; 12(6):533-41. PubMed ID: 17852440
    [Abstract] [Full Text] [Related]

  • 16. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 21; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 21; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
    Cortesi E, Mancuso A, De Pasquale Ceratti A, Pizzardi N, D'Auria G, Accettura C, Beccaglia P, Bertelletti D, De Marinis F.
    Oncologist; 2004 Jun 21; 9(4):459-68. PubMed ID: 15266099
    [Abstract] [Full Text] [Related]

  • 19. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
    Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB.
    Cancer; 2003 Mar 01; 97(5):1312-20. PubMed ID: 12599240
    [Abstract] [Full Text] [Related]

  • 20. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Mar 01; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.